Mersana Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

Rhea-AI Summary

Mersana Therapeutics (NASDAQ:MRSN) announced that CEO Anna Protopapas will present at the Jefferies Virtual Global Healthcare Conference on June 3 at 9:00 a.m. ET. The presentation will be available via live webcast on Mersana's website, with an archived replay accessible for 90 days post-event.

Mersana is focused on developing antibody-drug conjugates (ADCs) for cancer treatment. Their leading candidate, XMT-1536, is in a Phase 1 study for ovarian cancer and NSCLC adenocarcinoma. Another ADC, XMT-1592, targets NaPi2b-expressing tumors and is in dose escalation stages.

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that Anna Protopapas, President and Chief Executive Officer, will present at the Jefferies Virtual Global Healthcare Conference on Wednesday, June 3, at 9:00 a.m. ET.  

A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at www.mersana.com. An archived replay will be available for approximately 90 days following the presentation.

About Mersana Therapeutics

Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, XMT-1536, is in the expansion portion of a Phase 1 proof-of-concept clinical study in patients with ovarian cancer and NSCLC adenocarcinoma. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose escalation portion of a Phase 1 proof-of-concept clinical study. The Company’s early stage programs include a B7-H4 targeting ADC, as well as a STING agonist ADC developed using the Company’s Immunosynthen platform. In addition, multiple partners are using Mersana’s Dolaflexin platform to advance their ADC pipelines.

Contact:

Investor & Media Contact
Sarah Carmody
617-844-8577
scarmody@mersana.com 

FAQ

What is Mersana Therapeutics' stock symbol?

Mersana Therapeutics is traded under the stock symbol MRSN.

When will Anna Protopapas present at the Jefferies Conference?

Anna Protopapas will present on June 3 at 9:00 a.m. ET.

How can I watch the Mersana Therapeutics presentation?

The presentation can be watched via live webcast on Mersana's official website.

What are the main products being developed by Mersana Therapeutics?

Mersana is developing XMT-1536 for ovarian cancer and NSCLC, and XMT-1592 for NaPi2b-expressing tumors.

How long will the webcast replay of Mersana Therapeutics' presentation be available?

The archived replay will be available for approximately 90 days following the presentation.